Pharma companies are betting big on drugs that treat MASH, a serious liver disease linked to obesity and metabolic issues. Several companies have snapped up experimental drugs this year, including Roach and Novon Nordisk, which uh each have agreed to acquire liver disease focused companies and deals potentially worth several billion dollars a piece. The moves follow successful launch of Magical's drug res, which was the first match drug cleared by the FDA back in March 2024.For more in the increasingly comp ...